Research

Research Resilience Disappointing Alzheimer’s trial yields new ideas

Bapineuzumab and placebo

DAD (Disability Assessment for Dementia) scores worsened on average during the 78-week trial, with “bapi” (dotted blue line) showing no improvement over placebo.

A new study in the New England Journal of Medicine documents the high-profile failure of a promising drug, bapineuzumab, to slow cognitive decline in dementia patients. Dr. Stephen Salloway, the study’s lead author, says researchers have learned key lessons that they are eager to apply in new attempts to find effective treatments for Alzheimer’s disease.